Events

View All
    Join BIOCYTOGEN at PEGS Europe 2026

    Join BIOCYTOGEN at PEGS Europe 2026

    November 16, 2026
    Share on:

    We are excited to attend PEGS Europe 2026 from November 16th - 19th in Lisbon, Portugal. Join us at Europe’s largest protein and antibody engineering event to connect with colleagues across the biologics community and discover the latest advances in autoimmune and oncology research and therapeutics. Our experts will be at Booth #230, showcasing our AI-powered antibody discovery platform, fully human antibody assets, and target-humanized mouse models supporting the discovery and preclinical research of next-generation biologics, including ADCs, bispecific antibodies, and T-cell engagers. 

     

    What is PEGS Europe 2026?

    PEGS Europe 2026 brings together 1,500+ professionals to explore advances in protein and antibody engineering. This year’s program expands its focus on machine learning and AI, multispecific antibodies, next-generation conjugates, peptide drug discovery, and T-cell engagers. 

     

    Event Overview  

    Date: November 16th - 19th, 2026 

    Venue: Lisbon Congress Center, Praça das Indústrias 1, 1300-307 Lisboa, Portugal

    Booth: 230

     

    Posters

    • CRB2104: A Novel AMHR2/CD3 T cell Engager with Potent Antitumor Activity and Mitigated CRS Risk in AMHR2+ Solid Tumors

    • BCG015: A First-in-Class Antibody-Drug Conjugate Targeting TM4SF5 for the Treatment of Hepatocellular Carcinoma

    • RenSuper Workstation™: An AI-Powered, Closed-Loop In Vivo Discovery and Automation Engine for High-Efficiency Therapeutic Antibody Generation Infrastructure

    • BCG015: Novel Blood-Brain Barrier Penetrating Heavy Chain-Only Antibodies Targeting CD98


     

    About BIOCYTOGEN

    Biocytogen (SSE: 688796; HKEX: 02315) is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen has established a dual-engine platform combining a fully human antibody library with an extensive target-humanized mouse model portfolio, enabling a systematic approach to accelerating global drug discovery and development.

    Biocytogen has independently developed its proprietary RenMice® (RenMab®/RenLite®/RenNano®/RenTCR™/RenTCR mimic™) platforms for fully human monoclonal/bispecific/multispecific antibody discovery, bispecific antibody-drug conjugate discovery, hu-VHH discovery, and TCR mimic antibody discovery, and has established a sub-brand, RenSuper™ Biologics, to explore global partnerships for an off-the-shelf library of >1,000,000 fully human antibody sequences against over 1000 targets for worldwide collaboration. As of December 31, 2025, more than 350 agreements for therapeutic antibodies and clinical assets—spanning co-development, out-licensing, and transfers—have been established globally, including landmark partnerships with leading multinational pharmaceutical companies (MNCs). Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company's sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen, Jiangsu, Shanghai), the USA (Boston, San Francisco, San Diego), and Germany (Heidelberg). For more information, please visit https://biocytogen.com.